ArticleClinical cardiology2026
Targeted Superior Vena Cava Isolation Combined With Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Cryoballoon Ablation for Atrial Fibrillation.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe superior vena cava (SVC) is a common non-pulmonary vein (non-PV) trigger site in atrial fibrillation (AF), but its triggers are frequently underdetected without systematic mapping and provocation maneuvers. This study aimed to assess the temporal trend in SVC trigger detection rates and compare the efficacy and safety of cryoballoon-based targeted SVC isolation combined with pulmonary vein isolation (PVI) versus PVI alone.
methodsA retrospective analysis was conducted on 990 consecutive patients who underwent cryoballoon ablation for AF between January 2020 and December 2024. Annual SVC trigger detection rates were assessed using the Cochran-Armitage trend test. After excluding redo cases and performing 1:1 propensity score matching, 55 matched pairs were compared in terms of procedural outcomes, complications, and 12-month freedom from atrial tachyarrhythmias.
resultsSVC trigger detection rates increased significantly over the study period, from 6.8% in 2020 to 21.3% in 2024 (P for trend = 0.023). After matching, the PVI + SVCI group showed significantly higher 12-month freedom from atrial tachyarrhythmias compared to the PVI-only group (90.9% vs. 76.4%, p = 0.037). Procedural time was modestly longer in the PVI + SVCI group (93 ± 26 min vs. 80 ± 20 min, p = 0.003), but fluoroscopy time (12 ± 5 min vs. 10 ± 4 min, p = 0.276) and complication rates (5.5% vs. 3.6%, p = 0.500) were comparable between groups, both with low overall complication rates.
conclusionCryoballoon-based targeted SVC isolation guided by systematic mapping and provocation maneuvers significantly enhances freedom from atrial tachyarrhythmias without compromising safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.